Paul W. Wright
University of Virginia
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Paul W. Wright.
Developmental Biology | 2003
Paul W. Wright; Laura C. Bolling; Meredith E. K. Calvert; Olga F. Sarmento; Elizabeth V. Berkeley; Margaret C. Shea; Zhonglin Hao; Friederike Jayes; Leigh Ann Bush; Jagathpala Shetty; Amy Shore; P. Prabhakara Reddi; Kenneth S. K. Tung; Eileen T. Samy; Margaretta Allietta; Nicholas E. Sherman; John C. Herr; Scott A. Coonrod
Selected for its high relative abundance, a protein spot of MW approximately 75 kDa, pI 5.5 was cored from a Coomassie-stained two-dimensional gel of proteins from 2850 zona-free metaphase II mouse eggs and analyzed by tandem mass spectrometry (TMS), and novel microsequences were identified that indicated a previously uncharacterized egg protein. A 2.4-kb cDNA was then amplified from a mouse ovarian adapter-ligated cDNA library by RACE-PCR, and a unique 2043-bp open reading frame was defined encoding a 681-amino-acid protein. Comparison of the deduced amino acid sequence with the nonredundant database demonstrated that the protein was approximately 40% identical to the calcium-dependent peptidylarginine deiminase (PAD) enzyme family. Northern blotting, RT-PCR, and in situ hybridization analyses indicated that the protein was abundantly expressed in the ovary, weakly expressed in the testis, and absent from other tissues. Based on the homology with PADs and its oocyte-abundant expression pattern, the protein was designated ePAD, for egg and embryo-abundant peptidylarginine deiminase-like protein. Anti-recombinant ePAD monospecific antibodies localized the molecule to the cytoplasm of oocytes in primordial, primary, secondary, and Graafian follicles in ovarian sections, while no other ovarian cell type was stained. ePAD was also expressed in the immature oocyte, mature egg, and through the blastocyst stage of embryonic development, where expression levels began to decrease. Immunoelectron microscopy localized ePAD to egg cytoplasmic sheets, a unique keratin-containing intermediate filament structure found only in mammalian eggs and in early embryos, and known to undergo reorganization at critical stages of development. Previous reports that PAD-mediated deimination of epithelial cell keratin results in cytoskeletal remodeling suggest a possible role for ePAD in cytoskeletal reorganization in the egg and early embryo.
Journal of Biological Chemistry | 2016
Judith A. Woodfolk; Jill Glesner; Paul W. Wright; Christopher L. Kepley; Mi Li; Martin Himly; Lyndsey M. Muehling; Alla Gustchina; Alexander Wlodawer; Martin D. Chapman; Anna Pomés
Bla g 2 is a major indoor cockroach allergen associated with the development of asthma. Antigenic determinants on Bla g 2 were analyzed by mutagenesis based on the structure of the allergen alone and in complex with monoclonal antibodies that interfere with IgE antibody binding. The structural analysis revealed mechanisms of allergen-antibody recognition through cation-π interactions. Single and multiple Bla g 2 mutants were expressed in Pichia pastoris and purified. The triple mutant K132A/K251A/F162Y showed an ∼100-fold reduced capacity to bind IgE, while preserving the native molecular fold, as proven by x-ray crystallography. This mutant was still able to induce mast cell release. T-cell responses were assessed by analyzing Th1/Th2 cytokine production and the CD4+ T-cell phenotype in peripheral blood mononuclear cell cultures. Although T-cell activating capacity was similar for the KKF mutant and Bla g 2 based on CD25 expression, the KKF mutant was a weaker inducer of the Th2 cytokine IL-13. Furthermore, this mutant induced IL-10 from a non-T-cell source at higher levels that those induced by Bla g 2. Our findings demonstrate that a rational design of site-directed mutagenesis was effective in producing a mutant with only 3 amino acid substitutions that maintained the same fold as wild type Bla g 2. These residues, which were involved in IgE antibody binding, endowed Bla g 2 with a T-cell modulatory capacity. The antigenic analysis of Bla g 2 will be useful for the subsequent development of recombinant allergen vaccines.
The Journal of Infectious Diseases | 2018
Lyndsey M. Muehling; Ronald B. Turner; Kenneth B. Brown; Paul W. Wright; James T. Patrie; Sampo J. Lahtinen; Markus J. Lehtinen; William W. Kwok; Judith A. Woodfolk
Background Little is known about T cells that respond to human rhinovirus in vivo, due to timing of infection, viral diversity, and complex T-cell specificities. We tracked circulating CD4+ T cells with identical epitope specificities that responded to intranasal challenge with rhinovirus (RV)-A39, and we assessed T-cell signatures in the nose. Methods Cells were monitored using a mixture of 2 capsid-specific major histocompatibility complex II tetramers over a 7-week period, before and after RV-A39 challenge, in 16 human leukocyte antigen-DR4+ subjects who participated in a trial of Bifidobacterium lactis (Bl-04) supplementation. Results Pre-existing tetramer+ T cells were linked to delayed viral shedding, enriched for activated CCR5+ Th1 effectors, and included a minor interleukin-21+ T follicular helper cell subset. After RV challenge, expansion and activation of virus-specific CCR5+ Th1 effectors was restricted to subjects who had a rise in neutralizing antibodies, and tetramer-negative CCR5+ effector memory types were comodulated. In the nose, CXCR3-CCR5+ T cells present during acute infection were activated effector memory type, whereas CXCR3+ cells were central memory type, and cognate chemokine ligands were elevated over baseline. Probiotic had no T-cell effects. Conclusions We conclude that virus-specific CCR5+ effector memory CD4+ T cells primed by previous exposure to related viruses contribute to the control of rhinovirus.
Genesis | 2001
Scott A. Coonrod; Laura C. Bolling; Paul W. Wright; Pablo E. Visconti; John C. Herr
The Journal of Allergy and Clinical Immunology | 2010
Amanda J. Reefer; Kathryn E. Hulse; Josephine A. Lannigan; Michael D. Solga; Paul W. Wright; L.A. Kelly; James T. Patrie; Martin D. Chapman; Judith A. Woodfolk
Developmental Biology | 2005
Alejandra Vitale; Julie R. Perlin; Lauriebeth Leonelli; John C. Herr; Paul W. Wright; Laura Digilio
The Journal of Allergy and Clinical Immunology | 2016
Lyndsey M. Muehling; Ronald B. Turner; Rachana Agrawal; Paul W. Wright; James T. Patrie; Sampo J. Lahtinen; Markus J. Lehtinen; William W. Kwok; Judith A. Woodfolk
The Journal of Allergy and Clinical Immunology | 2015
Anna Pomés; Jill Glesner; Judith A. Woodfolk; Paul W. Wright; Christopher L. Kepley; Mi Li; Martin Himly; Alla Gustchina; Alexander Wlodawer; Martin D. Chapman
The Journal of Allergy and Clinical Immunology | 2012
Paul W. Wright; Jill Glesner; Martin D. Chapman; Anna Pomés; Judith A. Woodfolk
The Journal of Allergy and Clinical Immunology | 2012
Rachana Agrawal; Paul W. Wright; Judith A. Woodfolk